相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults
Xi-Ling Jiang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel Insights from the ELEVATE-TIMI 56 Trial
Edward T. Carreras et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Xi-Ling Jiang et al.
CLINICAL PHARMACOKINETICS (2015)
Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans
E. K. Tarkiainen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics
Nassim Djebli et al.
DRUG METABOLISM AND DISPOSITION (2015)
2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Ezra A. Amsterdam et al.
CIRCULATION (2014)
Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study
K. E. Kristensen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Effectiveness of Clopidogrel Dose Escalation to Normalize Active Metabolite Exposure and Antiplatelet Effects in CYP2C19 Poor Metabolizers
Richard B. Horenstein et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study
Joseph A. Jakubowski et al.
THROMBOSIS RESEARCH (2014)
Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading
In-Suk Kim et al.
AMERICAN HEART JOURNAL (2013)
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Patrick T. O'Gara et al.
CIRCULATION (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
Joshua P. Lewis et al.
PHARMACOGENETICS AND GENOMICS (2013)
Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation
Hao-Jie Zhu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Impact of Obesity on Drug Metabolism and Elimination in Adults and Children
Margreke J. E. Brill et al.
CLINICAL PHARMACOKINETICS (2012)
Clopidogrel: A Case for Indication-Specific Pharmacogenetics
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Influence of Genetic Polymorphisms on the Effect of High-and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention The GIFT (Genotype Information and Functional Testing) Study
Matthew J. Price et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
PharmGKB summary: very important pharmacogene information for CYP1A2
Caroline F. Thorn et al.
PHARMACOGENETICS AND GENOMICS (2012)
Simultaneous Absolute Protein Quantification of Carboxylesterases 1 and 2 in Human Liver Tissue Fractions using Liquid Chromatography-Tandem Mass Spectrometry
Yuichiro Sato et al.
DRUG METABOLISM AND DISPOSITION (2012)
High Doses of Clopidogrel to Overcome Genetic Resistance The Randomized Crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
Jean-Philippe Collet et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention The GRAVITAS Randomized Trial
Matthew J. Price et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Alain Li-Wan-Po et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Miho Kazui et al.
DRUG METABOLISM AND DISPOSITION (2010)
Genotyping One Piece of the Puzzle to Personalize Antiplatelet Therapy
Paul A. Gurbel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Guillaume Pare et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PharmGKB summary: very important pharmacogene information for CYP2B6
Caroline F. Thorn et al.
PHARMACOGENETICS AND GENOMICS (2010)
A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel
Katsunobu Hagihara et al.
DRUG METABOLISM AND DISPOSITION (2009)
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Dirk Sibbing et al.
EUROPEAN HEART JOURNAL (2009)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Obesity-induced hepatic hypoperfusion primes for hepatic dysfunction after resuscitated hemorrhagic shock
Paul J. Matheson et al.
SURGERY (2009)
Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of Clopidogrel before percutaneous coronary intervention
Dirk Sibbing et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Impact of P-glycoprotein on clopidogrel absorption
Dirk Taubert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction
T Gordi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
分享论文
